- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating ALK Inhibitor Toxicities
Panelists discuss how ALK inhibitors compare in terms of tolerability and best practices for managing associated toxicities.
EP: 1.The Evolution of ALK+ NSCLC Care
EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3
EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC
EP: 5.Key Differences Among ALK Inhibitors
EP: 6.Navigating ALK Inhibitor Toxicities
EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization
EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
EP: 11.Education and Support After Progression ALK Inhibitors
EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
ALK Inhibitor Tolerability and Toxicity Management
Key Themes:
- Tolerability comparison among available ALK inhibitors
- Best practices for managing treatment-associated toxicities
- Patient management strategies
Notable Insights:
- Castronovo compared the tolerability profiles of various ALK inhibitors
Grizzard shared best practices for toxicity management
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
June 23rd 2025The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
Read More
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
June 19th 2025Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Read More
